BOCA RATON, FL -- (Marketwire) -- 09/16/08 -- Vicor Technologies, Inc. (OTCBB: VCRT) today
announced publication of the results of its first clinical study conducted
in collaboration with the U.S. Army Institute of Surgical Research
(USAISR). Vicor Technologies is a biotechnology company that has developed
the PD2i, a patented, proprietary algorithm that is now in trials for FDA
510(k) approval for a) measuring heart rate variability (PD2i Analyzer), b)
risk stratifying combat and civilian trauma victims (PD2i VS), and c)
identifying patients at risk of suffering sudden cardiac death (PD2i CA).
The study is an analysis of data obtained from electrocardiograms of 11
combat casualty victims using nonlinear methods including Vicor's PD2i
Analyzer All of the wounded soldiers demonstrated abnormal heart rate
variability (HRV). Those requiring immediate life saving intervention all
had minimum PD2i values less than one. Entitled "Exploration of Heart-rate
complexity to determine the need for lifesaving interventions in combat
casualties," the study appears in the Journal of Critical Care (Volume 23,
Issue 2, Pages 265-266).
"This study clearly demonstrates the unique ability of Vicor's PD2i
Analyzer to accurately measure heart rate variability and the utility of
HRV measure in diagnosing the need for immediate life saving intervention,"
stated Mr. David Fater, Vicor Technologies' President and CEO. "We expect
that future studies of the PD2i Analyzer's effectiveness will prove equally
positive and further our efforts to commercialize the PD2i Analyzer, for
measuring heart rate variability, generally, and the PD2i VS, for risk
stratifying combat and civilian trauma victims, specifically," Mr. Fater
concluded.
Vicor Technologies and the U.S. Army Institute of Surgical Research
(USAISR) entered into a Collaborative Research and Development Agreement
(CRADA) for the "Prediction of Injury Severity and Outcome in the
Critically Ill Using the Point Correlation Dimension Algorithm, or PD2i" in
January 2008. Under the CRADA, the USAISR and Vicor are testing the
efficacy of the PD2i Analyzer as a vital sign application on four distinct
cohorts: animal trauma, human trauma, combat casualties, and burn victims.
About Vicor Technologies, Inc.
Vicor Technologies, Inc. (OTCBB: VCRT) is a development-stage biotechnology
company focused on the development of innovative diagnostics. Vicor's PD2i
Analyzer, PD2i Vital Sign (PD2i VS), and PD2i Cardiac Analyzer (PD2i CA)
employ the firm's patented, proprietary point correlation dimension
algorithm (PD2i), a deterministic, non-linear analytic measure that
accurately evaluates electrophysiological potentials with high sensitivity
and high specificity to predict future pathological events.
The PD2i Analyzer measures heart rate variability (HRV) through the
analysis of electrocardiographic data.
